Control of mature protein function by allosteric disulfide bonds

Antioxidants and Redox Signaling

Volumn 14, Issue 1, 2011, Pages 113-126

  Azimi, Iman ^a   Wong, Jason W H ^a   Hogg, Philip J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARYL SULFOTRANSFERASE; BETA2 GLYCOPROTEIN 1; BETA3 INTEGRIN; BOTULINUM TOXIN; CD4 ANTIGEN; CYSTEINE; DISULFIDE; PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ALLOSTERISM; ATOM; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CONTROLLED STUDY; DISULFIDE BOND; ELECTRON; ELECTRON TRANSPORT; HUMAN; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; REVIEW; STEREOCHEMISTRY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; DISULFIDES; HUMANS; PROTEIN STRUCTURE, TERTIARY; PROTEINS;

EID: 78649484651     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2010.3620     Document Type: Review

References (108)

1. Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, and Ruf W. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 103: 13932-13937, 2006.
2. Auwerx J, Isacsson O, Soderlund J, Balzarini J, Johansson M, and Lundberg M. Human glutaredoxin-1 catalyzes the reduction of HIV-1 gp120 and CD4 disulfides and its inhibition reduces HIV-1 replication. Int J Biochem Cell Biol 41: 1269-1275, 2009.
3. Azimi I, Matthias LJ, Center RJ, Wong JWH, and Hogg PJ. The disulfide bond that constrains the HIV-1 gp120 V3 domain is cleaved by thioredoxin. J Biol Chem (In press).
4. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 26: 456-461, 2006.
5. Barbouche R, Miquelis R, Jones IM, and Fenouillet E. Protein-disulfide isomerase-mediated reduction of two di-sulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. J Biol Chem 278: 3131-3136, 2003.
6. Begg GE, Carrington L, Stokes PH, Matthews JM, Wouters MA, Husain A, Lorand L, Iismaa SE, and Graham RM. Mechanism of allosteric regulation of transglutaminase 2 by GTP. Proc Natl Acad Sci USA 103: 19683-19688, 2006.
7. Berndt C, Lillig CH, and Holmgren A. Thioredoxins and glutaredoxins as facilitators of protein folding. Biochim Biophys Acta 1783: 641-650, 2008.
8. Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, and Gros P. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 18: 5166-5174, 1999.
9. Bourgeois R, Mercier J, Paquette-Brooks I, and Cohen EA. Association between disruption of CD4 receptor dimer-ization and increased human immunodeficiency virus type 1 entry. Retrovirology 3: 31, 2006.
10. Brooks DJ, Fresco JR, Lesk AM, and Singh M. Evolution of amino acid frequencies in proteins over deep time: inferred order of introduction of amino acids into the genetic code. Mol Biol Evol 19: 1645-1655, 2002.
11. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, and Hogg PJ. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 45: 12020-12028, 2006.
12. Chen VM and Hogg PJ. Allosteric disulfide bonds in thrombosis and thrombolysis. J Thromb Haemost 4: 2533-2541, 2006.
13. Cho J, Furie BC, Coughlin SR, and Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest 118: 1123-1131, 2008.
14. Choi H, Aboulfatova K, Pownall HJ, Cook R, and Dong JF. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J Biol Chem 282: 35604-35611, 2007.
15. Chung SI and Folk JE. Mechanism of the inactivation of guinea pig liver transglutaminase by tetrathionate. J Biol Chem 245: 681-689, 1970.
16. Collet JF, Riemer J, Bader MW, and Bardwell JC. Recon-stitution of a disulfide isomerization system. J Biol Chem 277: 26886-26892, 2002.
17. 0-dithiobis-(2-nitrobenzoic acid). J Biol Chem 244: 3173-3181, 1969.
18. Counts RB, Paskell SL, and Elgee SK. Disulfide bonds and the quaternary structure of factor VIII=von Willebrand factor. J Clin Invest 62: 702-709, 1978.
19. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 3: 1710-1716, 2005.
20. Einfeld D. Maturation and assembly of retroviral glyco-proteins. Curr Top Microbiol Immunol 214: 133-176, 1996.
21. Essex DW. Redox control of platelet function. Antioxid Re-dox Signal 11: 1191-1225, 2009.
22. Essex DW, Chen K, and Swiatkowska M. Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane. Blood 86: 2168-2173, 1995.
23. Essex DW and Li M. Redox control of platelet aggregation. Biochemistry 42: 129-136, 2003.
24. Fernandes PA and Ramos MJ. Theoretical insights into the mechanism for thiol=disulfide exchange. Chemistry 10: 257-266, 2004.
25. Fischer A and Montal M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem 282: 29604-29611, 2007.
26. Furie B and Furie BC. Mechanisms of thrombus formation. N Engl J Med 359: 938-949, 2008.
27. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol 72: 341-348, 1996.
28. Gallina A, Hanley TM, Mandel R, Trahey M, Broder CC, Viglianti GA, and Ryser HJ. Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J Biol Chem 277: 50579-50588, 2002.
29. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, and Blumenthal R. The HIV Env-mediated fusion reaction. Biochim Biophys Acta 1614: 36-50, 2003.
30. Ganderton T, Berndt MC, Chesterman CN, and Hogg PJ. Hypothesis for control of von Willebrand factor multimer size by intra-molecular thiol-disulphide exchange. J Thromb Haemost 5: 204-206, 2007.
31. Garcia Abreu J, Coffinier C, Larrain J, Oelgeschlager M, and De Robertis EM. Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems. Gene 287: 39-47, 2002.
32. Garrett TP, Wang J, Yan Y, Liu J, and Harrison SC. Refinement and analysis of the structure of the first two domains of human CD4. J Mol Biol 234: 763-778, 1993.
33. Giannakopoulos B, Passam F, Ioannou Y, and Krilis SA. How we diagnose the antiphospholipid syndrome. Blood 113: 985-994, 2009.
34. Gonzalez S, Groh V, and Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298: 121-138, 2006.
35. Gopalan G, He Z, Balmer Y, Romano P, Gupta R, Heroux A, Buchanan BB, Swaminathan K, and Luan S. Structural analysis uncovers a role for redox in regulating FKBP13, an immunophilin of the chloroplast thylakoid lumen. Proc Natl Acad Sci USA 101: 13945-13950, 2004.
36. Griffin M, Casadio R, and Bergamini CM. Transglutami-nases: nature's biological glues. Biochem J 368: 377-396, 2002.
37. Grimshaw JP, Stirnimann CU, Brozzo MS, Malojcic G, Grutter MG, Capitani G, and Glockshuber R. DsbL and DsbI form a specific dithiol oxidase system for periplasmic arylsulfate sulfotransferase in uropathogenic Escherichia coli. J Mol Biol 380: 667-680, 2008.
38. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, and Spies T. Cell stress-regulated human major histo-compatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93: 12445-12450, 1996.
39. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, and Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96: 6879-6884, 1999.
40. Hogg PJ. Disulfide bonds as switches for protein function. Trends Biochem Sci 28: 210-214, 2003.
41. Huang CC, Stricher F, Martin L, Decker JM, Majeed S, Barthe P, Hendrickson WA, Robinson J, Roumestand C, Sodroski J, Wyatt R, Shaw GM, Vita C, and Kwong PD. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 13: 755-768, 2005.
42. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687, 2002.
43. Ioannou Y, Zhang J-Y, Passam FH, Rahgozar S, Qi JC, Giannakopoulos B, Yu MQP, Yu DM, Hogg PJ, and Krilis SA. Naturally occurring free thiols within ß2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells and regulation of oxidative stress induced cell injury. Blood 116: 1995-1997, 2010.
44. Jacob-Dubuisson F, Pinkner J, Xu Z, Striker R, Padmanha-ban A, and Hultgren SJ. PapD chaperone function in pilus biogenesis depends on oxidant and chaperone-like activities of DsbA. Proc Natl Acad Sci USA 91: 11552-11556, 1994.
45. Jiang XM, Fitzgerald M, Grant CM, and Hogg PJ. Redox control of exofacial protein thiols=disulfides by protein disulfide isomerase. J Biol Chem 274: 2416-2423, 1999.
46. Jones DT, Taylor WR, and Thornton JM. The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci 8: 275-282, 1992.
47. Jordan IK, Kondrashov FA, Adzhubei IA, Wolf YI, Koonin EV, Kondrashov AS, and Sunyaev S. A universal trend of amino acid gain and loss in protein evolution. Nature 433: 633-638, 2005.
48. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, Strong RK, Groh V, and Spies T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447: 482-486, 2007.
49. Krause G, Lundstrom J, Barea JL, Pueyo de la Cuesta C, and Holmgren A. Mimicking the active site of protein disulfide-isomerase by substitution of proline 34 in Es-cherichia coli thioredoxin. J Biol Chem 266: 9494-9500, 1991.
50. Lai TS, Liu Y, Tucker T, Daniel KR, Sane DC, Toone E, Burke JR, Strittmatter WJ, and Greenberg CS. Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem Biol 15: 969-978, 2008.
51. Le DT, Rapaport SI, and Rao LV. Relations between factor VIIa binding and expression of factor VIIa=tissue factor catalytic activity on cell surfaces. J Biol Chem 267: 15447-15454, 1992.
52. Li P, Morris DL, Willcox BE, Steinle A, Spies T, and Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2: 443-451, 2001.
53. Li P, Willie ST, Bauer S, Morris DL, Spies T, and Strong RK. Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity 10: 577-584, 1999.
54. Li Y, Choi H, Zhou Z, Nolasco L, Pownall HJ, Voorberg J, Moake JL, and Dong JF. Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions. J Thromb Haemost 6: 1135-1143, 2008.
55. Liang HP and Hogg PJ. Critical importance of the cell system when studying tissue factor de-encryption. Blood 112: 912-913; author reply 913, 2008.
56. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, and Sub-ramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113, 2008.
57. Luken BM, Winn LY, Emsley J, Lane DA, and Crawley JT. The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function. Blood 115:4910- 4913, 2010.
58. Lundstrom J and Holmgren A. Determination of the reduction-oxidation potential of the thioredoxin-like domains of protein disulfide-isomerase from the equilibrium with glu-tathione and thioredoxin. Biochemistry 32: 6649-6655, 1993.
59. Maekawa A, Schmidt B, Fazekas de St Groth B, Sanejouand YH, and Hogg PJ. Evidence for a domain-swapped CD4 dimer as the coreceptor for binding to class II MHC. J Immunol 176: 6873-6878, 2006.
60. Malojcic G, Owen RL, Grimshaw JP, Brozzo MS, Dreher-Teo H, and Glockshuber R. A structural and biochemical basis for PAPS-independent sulfuryl transfer by aryl sul-fotransferase from uropathogenic Escherichia coli. Proc Natl Acad Sci USA 105: 19217-19222, 2008.
61. Markovic I, Stantchev TS, Fields KH, Tiffany LJ, Tomic M, Weiss CD, Broder CC, Strebel K, and Clouse KA. Thiol=disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood 103: 1586-1594, 2004.
62. Matthias LJ, Azimi I, Tabrett CA, and Hogg PJ. Reduced monomeric CD4 is the preferred receptor for HIV. J Biol Chem 2010 Oct 25 [Epub ahead of print].
63. Matthias LJ, Yam PT, Jiang XM, Vandegraaff N, Li P, Poumbourios P, Donoghue N, and Hogg PJ. Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol 3: 727-732, 2002.
64. Michaux G, Abbitt KB, Collinson LM, Haberichter SL, Norman KE, and Cutler DF. The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell 10: 223-232, 2006.
65. Mills JE, Whitford PC, Shaffer J, Onuchic JN, Adams JA, and Jennings PA. A novel disulfide bond in the SH2 domain of the C-terminal Src kinase controls catalytic activity. J Mol Biol 365: 1460-1468, 2007.
66. Miyakis S, Giannakopoulos B, and Krilis SA. Beta 2 gly-coprotein I-function in health and disease. Thromb Res 114: 335-346, 2004.
67. Moldovan MC, Yachou A, Levesque K, Wu H, Hen-drickson WA, Cohen EA, and Sekaly RP. CD4 dimers constitute the functional component required for T cell activation. J Immunol 169: 6261-6268, 2002.
68. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79: 591-617, 2010.
69. Mor-Cohen R, Rosenberg N, Landau M, Lahav J, and Seligsohn U. Specific cysteines in beta3 are involved in disulfide bond exchange-dependent and -independent activation of alphaIIbbeta3. J Biol Chem 283: 19235-19244, 2008.
70. Ogawa A, Takayama Y, Sakai H, Chong KT, Takeuchi S, Nakagawa A, Nada S, Okada M, and Tsukihara T. Structure of the carboxyl-terminal Src kinase, Csk. J Biol Chem 277: 14351-14354, 2002.
71. O'Leary JM, Hamilton JM, Deane CM, Valeyev NV, Sandell LJ, and Downing AK. Solution structure and dynamics of a prototypical chordin-like cysteine-rich repeat (von Will-ebrand Factor type C module) from collagen IIA. J Biol Chem 279: 53857-53866, 2004.
72. Ostergaard H, Henriksen A, Hansen FG, and Winther JR. Shedding light on disulfide bond formation: engineering a redox switch in green fluorescent protein. EMBO J 20: 5853-5862, 2001.
73. Ou W and Silver J. Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion. Virology 350: 406-417, 2006.
74. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JWH, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Giannakopoulos B, Hughes WE, Hogg PJ, and Krilis SA. Redox control of b2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. J Thromb Haemost 8: 1754-1762, 2010.
75. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JWH, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Hughes WE, Hogg PJ, and Krilis SA. Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood 116: 1995-1997, 2010.
76. Pendurthi UR, Ghosh S, Mandal SK, and Rao LV. Tissue factor activation: is disulfide bond switching a regulatory mechanism? Blood 110: 3900-3908, 2007.
77. Persson E. Protein disulfide isomerase has no stimulatory chaperone effect on factor X activation by factor VIIa-soluble tissue factor. Thromb Res 123: 171-176, 2008.
78. Piatek R, Zalewska B, Kolaj O, Ferens M, Nowicki B, and Kur J. Molecular aspects of biogenesis of Escherichia coli Dr Fimbriae: characterization of DraB-DraE complexes. Infect Immun 73: 135-145, 2005.
79. Pinkas DM, Strop P, Brunger AT, and Khosla C. Trans-glutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5: e327, 2007.
80. Ploplis VA, Edgington TS, and Fair DS. Initiation of the extrinsic pathway of coagulation. Association of factor VIIa with a cell line expressing tissue factor, J Biol Chem, 262, 9503-9508, 1987.
81. Raturi A, Miersch S, Hudson JW, and Mutus B. Platelet microparticle-associated protein disulfide isomerase promotes platelet aggregation and inactivates insulin. Biochim Biophys Acta 1778: 2790-2796, 2008.
82. Reinhardt C, von Bruhl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, Dlugai S, Hess S, Konrad I, Orschiedt L, Mackman N, Ruddock L, Massberg S, and Engelmann B. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 118: 1110-1122, 2008.
83. Richardson J and Richardson D. Prediction of Protein Structure and the Principles of Protein Conformation New York: Plenum Press, 1989, pp. 1-99.
84. Rozhkova A and Glockshuber R. Thermodynamic aspects of DsbD-mediated electron transport. J Mol Biol 380: 783-788, 2008.
85. Ryser HJ, Levy EM, Mandel R, and DiSciullo GJ. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci USA 91: 4559-4563, 1994.
86. Sakai T, Lund-Hansen T, Paborsky L, Pedersen AH, and Kisiel W. Binding of human factors VII and VIIa to a human bladder carcinoma cell line (J82). Implications for the initiation of the extrinsic pathway of blood coagulation. J Biol Chem 264: 9980-9988, 1989.
87. Sanejouand YH. Domain swapping of CD4 upon dimer-ization. Proteins 57: 205-212, 2004.
88. Sauer FG, Pinkner JS, Waksman G, and Hultgren SJ. Cha-perone priming of pilus subunits facilitates a topological transition that drives fiber formation. Cell 111: 543-551, 2002.
89. Schmidt B, Ho L, and Hogg PJ. Allosteric disulfide bonds. Biochemistry 45: 7429-7433, 2006.
90. Schmidt B and Hogg PJ. Search for allosteric disulfide bonds in NMR structures. BMC Struct Biol 7: 49, 2007.
91. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, and Prassl R. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 18: 6228-6239, 1999.
92. Schwertassek U, Balmer Y, Gutscher M, Weingarten L, Preuss M, Engelhard J, Winkler M, and Dick TP. Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1. EMBO J 26: 3086-3097, 2007.
93. Siegel M and Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115: 232-245, 2007.
94. Swaminathan S and Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 7: 693-699, 2000. (Pubitemid 30636683)
95. Swiatkowska M, Szymanski J, Padula G, and Cierniewski CS. Interaction and functional association of protein dis-ulfide isomerase with alphaVbeta3 integrin on endothelial cells. FEBS J 275: 1813-1823, 2008.
96. Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost 29: 479-488, 2003.
97. Versteeg HH and Ruf W. Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. J Biol Chem 282: 25416-25424, 2007.
98. Wiita AP, Perez-Jimenez R, Walther KA, Grater F, Berne BJ, Holmgren A, Sanchez-Ruiz JM, and Fernandez JM. Probing the chemistry of thioredoxin catalysis with force. Nature 450: 124-127, 2007.
99. Wong JWH, Ho SYW, and Hogg PJ. Disulfide bond acquisition through eukaryotic protein evolution. Mol Biol Evol 2010 Jul 30 [Epub ahead of print].
100. Wouters MA, Lau KK, and Hogg PJ. Cross-strand dis-ulphides in cell entry proteins: poised to act. Bioessays 26: 73-79, 2004.
101. Xie L, Chesterman CN, and Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 193: 1341-1349, 2001.
102. Xiong JP, Mahalingham B, Alonso JL, Borrelli LA, Rui X, Anand S, Hyman BT, Rysiok T, Muller-Pompalla D, Goodman SL, and Arnaout MA. Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha=beta transmembrane fragment. J Cell Biol 186: 589-600, 2009.
103. Zav'yalov VP, Chernovskaya TV, Chapman DA, Karlyshev AV, MacIntyre S, Zavialov AV, Vasiliev AM, Denesyuk AI, Zav'yalova GA, Dudich IV, Korpela T, and Abramov VM. Influence of the conserved disulphide bond, exposed to the putative binding pocket, on the structure and function of the immunoglobulin-like molecular chaperone Caf1M of Yersinia pestis. Biochem J 324 (Pt 2): 571-578, 1997.
104. Zhang JL, Huang Y, Qiu LY, Nickel J, and Sebald W. von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms. J Biol Chem 282: 20002-20014, 2007.
105. Zhang JL, Qiu LY, Kotzsch A, Weidauer S, Patterson L, Hammerschmidt M, Sebald W, and Mueller TD. Crystal structure analysis reveals how the Chordin family member crossveinless 2 blocks BMP-2 receptor binding. Dev Cell 14: 739-750, 2008.
106. Zhang Q, Zhou YF, Zhang CZ, Zhang X, Lu C, and Springer TA. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci USA 106: 9226-9231, 2009.
107. Zhang X, Halvorsen K, Zhang CZ, Wong WP, and Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 324: 1330-1334, 2009.
108. Zhu J, Luo BH, Xiao T, Zhang C, Nishida N, and Springer TA. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell 32: 849-861, 2008.